Paul Langlie Martin
Paul Langlie Martin

Paul Langlie Martin

Professor of Pediatrics

Overview

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as sickle cell disease, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.  We once again achieved a new record for the number of implanted patients during the 2022-2023 academic year.

Positions

Professor of Pediatrics in the School of Medicine

2021 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

1996 School of Medicine

Education

M.D. 1987

1987 Washington University in St. Louis

Ph.D. 1987

1987 Washington University in St. Louis

Intern, Pediatrics

1988 Yale University

Resident, Pediatrics

1989 Yale University

Fellow, Pediatric Hematology/Oncology, Pediatrics

1992 Yale University

Publications, Grants & Awards

Offices & Contact

2400 Pratt St
Durham, NC
27705
Box 102502 Med Ctr
Durham, NC
27710